Silvia Cristina Paiva Almeida

Silvia Cristina Paiva Almeida

Auto-generated profile, based on publicly available information

Silvia Cristina Paiva Almeida

Instituto Gulbenkian de Ciência, Oeiras, Portugal

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 April 2017 in Nature Communications
Verified
Journal Article
Open access
PDF file
AMAna Raquel Maceiras
Ana Raquel Maceiras
SASilvia Cristina Paiva Almeida
Silvia Cristina Paiva Almeida
EMEncarnita Mariotti-Ferrandiz
Encarnita Mariotti-Ferrandiz
WCWahiba Chaara
Wahiba Chaara
FJFadi Jebbawi
Fadi Jebbawi
LGLuis Graca
Luis Graca
Immunization leads to the formation of germinal centres (GCs) that contain both T follicular helper (Tfh) and T follicular regulatory (Tfr) cells. Whether T-cell receptor (TCR) specificity defines the differential functions of Tfh and Tfr cells is unclear. Here we show that antigen-specific T cells after immunization are preferentially recruited to the GC to become Tfh cells, but not Tfr cells. Tfh cells, but not Tfr cells, also proliferate efficiently on restimulation with the same immunizing antigenin vitro.Ex vivoTCR repertoire analysis shows that immunization induces oligoclonal expansion of Tfh cells. By contrast, the Tfr pool has a TCR repertoire that more closely resembles that of regulatory T (Treg) cells. Our data thus indicate that the GC Tfh and Tfr pools are generated from distinct TCR repertoires, with Tfh cells expressing antigen-responsive TCRs to promote antibody responses, and Tfr cells expressing potentially autoreactive TCRs to suppress autoimmunity.

4 January 2011 in Archives of Virology
Verified
Journal Article
Open access
PDF file
VOVivian Leite de Oliveira
Vivian Leite de Oliveira
SAS. C. P. Almeida
S. C. P. Almeida
HSH. R. Soares
H. R. Soares
ACA. Crespo
A. Crespo
SMS. Marshall-Clarke
S. Marshall-Clarke
MPMichael Parkhouse
Michael Parkhouse
African swine fever virus (ASFV) encodes proteins that manipulate important host antiviral mechanisms. Bioinformatic analysis of the ASFV genome revealed ORF I329L, a gene without any previous functional characterization as a possible inhibitor of TLR signaling. We demonstrate that ORF I329L encodes a highly glycosylated protein expressed in the cell membrane and on its surface. I329L also inhibited dsRNA-stimulated activation of NFκB and IRF3, two key players in innate immunity. Consistent with this, expression of I329L protein also inhibited the activation of interferon-β and CCL5. Finally, overexpression of TRIF reversed I329L-mediated inhibition of both NFκB and IRF3 activation. Our results suggest that TRIF, a key MyD88-independent adaptor molecule, is a possible target of this viral host modulation gene. The demonstration of an ASFV host evasion molecule inhibiting TLR responses is consistent with the ability of this virus to infect vertebrate and invertebrate hosts, both of which deploy innate immunity controlled by conserved TLR systems.

1 January 2015 in Stem Cells International
Verified
Journal Article
Open access
PDF file
RBR. N. Bárcia
R. N. Bárcia
JSJorge Miguel Silva Santos
Jorge Miguel Silva Santos
MFM. Filipe
M. Filipe
MTM. Teixeira
M. Teixeira
PMPaulo Martins
Paulo Martins
PCP. E. Cruz
P. E. Cruz
MSCs derived from the umbilical cord tissue, termed UCX, were investigated for their immunomodulatory properties and compared to bone marrow-derived MSCs (BM-MSCs), the gold-standard in immunotherapy. Immunogenicity and immunosuppression were assessed by mixed lymphocyte reactions, suppression of lymphocyte proliferation and induction of regulatory T cells. Results showed that UCX were less immunogenic and showed higher immunosuppression activity than BM-MSCs. Further, UCX did not need prior activation or priming to exert their immunomodulatory effects. This was further corroboratedin vivoin a model of acute inflammation. To elucidate the potency differences observed between UCX and BM-MSCs, gene expression related to immune modulation was analysed in both cell types. Several gene expression profile differences were found between UCX and BM-MSCs, namely decreased expression ofHLA-DRA,HO-1,IGFBP1, 4 and 6,ILR1,IL6RandPTGESand increased expression ofCD200,CD273,CD274,IL1B,IL-8,LIFandTGFB2. The latter were confirmed at the protein expression level. Overall, these results show that UCX seem to be naturally more potent immunosuppressors and less immunogenic than BM-MSCs. We propose that these differences may be due to increased levels of immunomodulatory surface proteins such as CD200, CD273, CD274 and cytokines such as IL1β, IL-8, LIF and TGFβ2.

17 January 2014 in Stem Cell Research & Therapy
Verified
Journal Article
Open access
PDF file
PMPaulo Martins
Paulo Martins
JSJorge Miguel Silva Santos
Jorge Miguel Silva Santos
JAJoana Martode Almeida
Joana Martode Almeida
MFMariana Alves Filipe
Mariana Alves Filipe
MAMariana Vargas Teixeira de Almeida
Mariana Vargas Teixeira de Almeida
RBRita Nogueira Bárcia
Rita Nogueira Bárcia
Introduction: Standardization of mesenchymal stromal cells (MSCs) manufacturing is urgently needed to enable translational activities and ultimately facilitate comparison of clinical trial results. In this work we describe the adaptation of a proprietary method for isolation of a specific umbilical cord tissue-derived population of MSCs, herein designated by its registered trademark as UCX®, towards the production of an advanced therapy medicinal product (ATMP). Methods: The adaptation focused on different stages of production, from cell isolation steps to cell culturing and cryopreservation. The origin and quality of materials and reagents were considered and steps for avoiding microbiological and endotoxin contamination of the final cell product were implemented. Cell isolation efficiency, MSCs surface markers and genetic profiles, originating from the use of different medium supplements, were compared. The ATMP-compliant UCX® product was also cryopreserved avoiding the use of dimethyl sulfoxide, an added benefit for the use of these cells as an ATMP. Cells were analyzed for expansion capacity and longevity. The final cell product was further characterized by flow cytometry, differentiation potential, and tested for contaminants at various passages. Finally, genetic stability and immune properties were also analyzed. Results: The isolation efficiency of UCX® was not affected by the introduction of clinical grade enzymes. Furthermore, isolation efficiencies and phenotype analyses revealed advantages in the use of human serum in cell culture as opposed to human platelet lysate. Initial decontamination of the tissue followed by the use of mycoplasma- and endotoxin-free materials and reagents in cell isolation and subsequent culture, enabled the removal of antibiotics during cell expansion. UCX®-ATMP maintained a significant expansion potential of 2.5 population doublings per week up to passage 15 (P15). They were also efficiently cryopreserved in a DMSO-free cryoprotectant medium with approximately 100% recovery and 98% viability post-thaw. Additionally, UCX®-ATMP were genetically stable upon expansion (up to P15) and maintained their immunomodulatory properties. Conclusions: We have successfully adapted a method to consistently isolate, expand and cryopreserve a well-characterized population of human umbilical cord tissue-derived MSCs (UCX®), in order to obtain a cell product that is compliant with cell therapy. Here, we present quality and safety data that support the use of the UCX® as an ATMP, according to existing international guidelines.

17 January 2013 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
JSJorge Miguel Silva Santos
Jorge Miguel Silva Santos
RBRita N Bárcia
Rita N Bárcia
Sandra SimõesSandra Simões
Sandra Simões
Maria Manuela GasparMaria Manuela Gaspar
Maria Manuela Gaspar
SCSusana Calado
Susana Calado
HCHelder Cruz
Helder Cruz
ECBio has developed proprietary technology to consistently isolate, expand and cryopreserve a well-characterized population of stromal cells from human umbilical cord tissue (UCX® cells). The technology has recently been optimized in order to become compliant with Advanced Medicine Therapeutic Products. In this work we report the immunosuppressive capacity of UCX® cells for treating induced autoimmune inflammatory arthritis.

1 March 2015 in Molecular Immunology
Verified
Journal Article
Closed access
ABAfonso Basto
Afonso Basto
MBMarina Badenes
Marina Badenes
SASílvia C.P. Almeida
Sílvia C.P. Almeida
CMCarlos Martins
Carlos Martins
ADAntonio Duarte
Antonio Duarte
ALAlexandre Leitão
Alexandre Leitão